• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人类CD4+ T细胞对B7-1/B7-2的结扎触发树突状细胞中的吲哚胺2,3-双加氧酶活性。

Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells.

作者信息

Munn David H, Sharma Madhav D, Mellor Andrew L

机构信息

Institute of Molecular Medicine and Genetics and Departments of Pediatrics, Medical College of Georgia, Augusta, GA 30912, USA.

出版信息

J Immunol. 2004 Apr 1;172(7):4100-10. doi: 10.4049/jimmunol.172.7.4100.

DOI:10.4049/jimmunol.172.7.4100
PMID:15034022
Abstract

Human monocyte-derived dendritic cells (DCs) are capable of expressing the tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO), which allows them to suppress Ag-driven proliferation of T cells in vitro. In DCs that express IDO, the activity of the enzyme is tightly regulated, with the protein being constitutively expressed, but functional activity requiring an additional set of triggering signals supplied during Ag presentation. We now show that triggering of functional IDO obligately requires ligation of B7-1/B7-2 molecules on the DCs by CTLA4/CD28 expressed on T cells. When this interaction was disrupted, IDO remained in the inactive state, and the DCs were unable to inhibit T cell proliferation. Inhibition could be fully restored by direct Ab-mediated cross-linking of B7-1/B7-2. Although both CD4(+) and CD8(+) T cells were susceptible to inhibition once IDO was induced, the ability to trigger functionally active IDO was strictly confined to the CD4(+) subset. Thus, the ability of CD4(+) T cells to induce IDO activity in DCs allowed the CD4(+) population to dominantly inhibit proliferation of the CD8(+) population via the bridge of a conditioned DC. We hypothesize that IDO activation via engagement of B7-1/B7-2 molecules on DCs, specifically, engagement by CTLA4 expressed on regulatory CD4(+) T cells, may function as a physiologic regulator of T cell responses in vivo.

摘要

人单核细胞衍生的树突状细胞(DCs)能够表达色氨酸降解酶吲哚胺2,3-双加氧酶(IDO),这使得它们能够在体外抑制抗原驱动的T细胞增殖。在表达IDO的DCs中,该酶的活性受到严格调控,其蛋白质组成性表达,但功能活性需要在抗原呈递过程中提供的另一组触发信号。我们现在表明,功能性IDO的触发必然需要T细胞上表达的CTLA4/CD28与DCs上的B7-1/B7-2分子结合。当这种相互作用被破坏时,IDO保持无活性状态,并且DCs无法抑制T细胞增殖。通过直接抗体介导的B7-1/B7-2交联可完全恢复抑制作用。虽然一旦诱导IDO,CD4(+)和CD8(+) T细胞都易受抑制,但触发功能性活性IDO的能力严格限于CD4(+)亚群。因此,CD4(+) T细胞在DCs中诱导IDO活性的能力使得CD4(+)群体能够通过条件性DC的桥梁主要抑制CD8(+)群体的增殖。我们推测,通过DCs上B7-1/B7-2分子的结合,特别是调节性CD4(+) T细胞上表达的CTLA4的结合来激活IDO,可能在体内作为T细胞反应的生理调节剂发挥作用。

相似文献

1
Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells.人类CD4+ T细胞对B7-1/B7-2的结扎触发树突状细胞中的吲哚胺2,3-双加氧酶活性。
J Immunol. 2004 Apr 1;172(7):4100-10. doi: 10.4049/jimmunol.172.7.4100.
2
Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells.CTLA-4-Fc对人CD4+ T细胞中吲哚胺2,3-双加氧酶和色氨酰-tRNA合成酶的调控
Blood. 2005 Feb 15;105(4):1574-81. doi: 10.1182/blood-2004-06-2089. Epub 2004 Oct 5.
3
Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase.在细胞毒性T淋巴细胞相关抗原4(CTLA4)介导的吲哚胺2,3-双加氧酶诱导后,小鼠树突状细胞的特定亚群获得强大的T细胞调节功能。
Int Immunol. 2004 Oct;16(10):1391-401. doi: 10.1093/intimm/dxh140. Epub 2004 Sep 6.
4
Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation.由CD40与B7激活介导的树突状细胞亚群的功能可塑性。
J Immunol. 2003 Sep 1;171(5):2581-7. doi: 10.4049/jimmunol.171.5.2581.
5
Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production.巨噬细胞上B7-H1的阻断通过增强干扰素-γ诱导的一氧化氮生成来抑制CD4+ T细胞增殖。
J Immunol. 2005 Aug 1;175(3):1586-92. doi: 10.4049/jimmunol.175.3.1586.
6
Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion.前沿:树突状细胞亚群中诱导型吲哚胺2,3-双加氧酶的表达抑制T细胞克隆扩增。
J Immunol. 2003 Aug 15;171(4):1652-5. doi: 10.4049/jimmunol.171.4.1652.
7
B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis.在慢性实验性结肠炎中,B7与CD28和CTLA-4的相互作用控制着耐受性或黏膜炎症的诱导。
J Immunol. 2001 Aug 1;167(3):1830-8. doi: 10.4049/jimmunol.167.3.1830.
8
A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation.一小部分表达CD19的脾树突状细胞在B7连接后通过I型干扰素信号传导介导依赖吲哚胺2,3-双加氧酶的T细胞抑制。
Int Immunol. 2005 Jul;17(7):909-19. doi: 10.1093/intimm/dxh271. Epub 2005 Jun 20.
9
Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation.人树突状细胞产生吲哚胺2,3-双加氧酶会导致T细胞增殖受到抑制。
J Immunol. 2000 Apr 1;164(7):3596-9. doi: 10.4049/jimmunol.164.7.3596.
10
The role of B7 costimulation in CD4/CD8 T cell homeostasis.B7共刺激在CD4/CD8 T细胞稳态中的作用。
J Immunol. 2000 Apr 1;164(7):3543-53. doi: 10.4049/jimmunol.164.7.3543.

引用本文的文献

1
Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy.用于个性化治疗和提高疗效的革命性癌症疗法:克服免疫检查点抑制剂疗法耐药性的策略
Cancers (Basel). 2025 Mar 4;17(5):880. doi: 10.3390/cancers17050880.
2
Overcoming immune evasion with innovative multi-target approaches for glioblastoma.采用创新的多靶点方法克服胶质母细胞瘤的免疫逃逸
Front Immunol. 2025 Jan 22;16:1541467. doi: 10.3389/fimmu.2025.1541467. eCollection 2025.
3
Single-cell RNA-sequencing of human spleens reveals an IDO-1 tolerogenic dendritic cell subset in pancreatic cancer patients that is absent in normal individuals.
单细胞 RNA 测序分析人类脾脏揭示,胰腺癌患者中的 IDO-1 耐受性树突状细胞亚群在正常个体中不存在。
Cancer Lett. 2024 Dec 28;607:217321. doi: 10.1016/j.canlet.2024.217321. Epub 2024 Nov 14.
4
Immunometabolism: signaling pathways, homeostasis, and therapeutic targets.免疫代谢:信号通路、稳态及治疗靶点
MedComm (2020). 2024 Nov 3;5(11):e789. doi: 10.1002/mco2.789. eCollection 2024 Nov.
5
Kynurenine Pathway after Kidney Transplantation: Friend or Foe?肾脏移植后的犬尿氨酸途径:是敌是友?
Int J Mol Sci. 2024 Sep 14;25(18):9940. doi: 10.3390/ijms25189940.
6
Unraveling Th subsets: insights into their role in immune checkpoint inhibitor therapy.解析T细胞亚群:洞察其在免疫检查点抑制剂治疗中的作用
Cell Oncol (Dordr). 2025 Apr;48(2):295-312. doi: 10.1007/s13402-024-00992-0. Epub 2024 Sep 26.
7
Berberine: A natural modulator of immune cells in multiple sclerosis.小檗碱:多发性硬化症中免疫细胞的天然调节剂。
Immun Inflamm Dis. 2024 Mar;12(3):e1213. doi: 10.1002/iid3.1213.
8
A new target of radiotherapy combined with immunotherapy: regulatory T cells.放疗联合免疫治疗的新靶点:调节性 T 细胞。
Front Immunol. 2024 Jan 8;14:1330099. doi: 10.3389/fimmu.2023.1330099. eCollection 2023.
9
Microbial metabolites are involved in tumorigenesis and development by regulating immune responses.微生物代谢物通过调节免疫应答参与肿瘤的发生和发展。
Front Immunol. 2023 Dec 19;14:1290414. doi: 10.3389/fimmu.2023.1290414. eCollection 2023.
10
Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial.基于吲哚莫德的化疗免疫治疗儿科脑肿瘤:儿童首个人体 I 期试验。
Neuro Oncol. 2024 Feb 2;26(2):348-361. doi: 10.1093/neuonc/noad174.